{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:24Z","timestamp":1787071284667,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hypofractionated Radiotherapy has replaced Conventional Radiotherapy in Carcinoma Breast. This study aimed to assess locoregional failure, disease-free survival, and overall survival in patients treated over 5 years in our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A total of 453 patients with carcinoma of the breast eligible for whole breast radiotherapy were assessed from January 2018 to December 2023. Two-dimensional Radiotherapy was given via Telecobalt or LINAC. Demographic, disease, and treatment-related data were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Median follow-up was 2.75 years (Range 0.3\u20135.2 years). Breast-conserving surgery and modified radical mastectomy were done in 21.81% and 78.18% of patients respectively. Neoadjuvant chemotherapy was given in 55.2% of cases. Pathologically, 54.2% of patients had Stage IIB\u2013IIIB and 45.7% had I\u2013IIA.70.84% were given 42 Gy\/15 # and the rest of them were given either 41.6 Gy\/16 # or 40 Gy\/15 #. Percentages of acute skin toxicities Grade I, II, and chronic were observed in 23.11%, 3.97%, and 5.07%, respectively. There were a total of 16 locoregional recurrences and 27 cases of distant metastasis in 5 years. Overall survival and disease-free survival after 5 years were 94.2% and 90.5%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Hypofractionated radiotherapy is a safe and efficacious choice for radical treatment of carcinoma breast patients post-surgery. It provides superlative results in concern to disease-free survival and overall survival with minimal acute and chronic toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_282_24","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:00:10Z","timestamp":1758906010000},"page":"995-999","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Hypofractionated radiotherapy in carcinoma breast - A 5-year single institution experience"],"prefix":"10.4103","volume":"21","author":[{"given":"Pardeep","family":"Garg","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navik","family":"Goyal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheenu","family":"Priya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romi","family":"Grover","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"R1-20250929","first-page":"409","article-title":"Breast cancer statistics, 2011","volume":"61","author":"DeSantis","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R3-20250929","doi-asserted-by":"crossref","first-page":"iv 107","DOI":"10.1093\/annonc\/mdu327.72","article-title":"327P - Survival analysis of breast cancer patients treated at a tertiary care centre in Southern India","volume":"25","author":"Arumugham","year":"2014","journal-title":"Ann Oncol"},{"issue":"(Suppl 2)","key":"R4-20250929","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12262-020-02388-4","article-title":"Current status of breast cancer management in India","volume":"83","author":"Maurya","year":"2021","journal-title":"Indian J Surg"},{"key":"R5-20250929","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1259\/0007-1285-25-300-636","article-title":"Radiotherapy in breast cancer. I. The dose-time relationship theoretical considerations","volume":"25","author":"Cohen","year":"1952","journal-title":"Br J Radiol"},{"key":"R6-20250929","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/0360-3016(82)90062-1","article-title":"Superfractionation:Its rationale and anticipated benefits","volume":"8","author":"Douglas","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20250929","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2020.09.004","article-title":"Trends in use of hypofractionated whole breast radiation in breast cancer:An analysis of the National Cancer Database","volume":"109","author":"Woodward","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20250929","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.radonc.2020.10.008","article-title":"Hypofractionated radiation therapy for breast cancer:Preferences amongst radiation oncologists in Europe:Results from an international survey","volume":"155","author":"Ratosa","year":"2021","journal-title":"Radiother Oncol"},{"key":"R9-20250929","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jnci\/94.15.1143","article-title":"Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer","volume":"94","author":"Whelan","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R10-20250929","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2005.01.005","article-title":"Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer:Long-term results of a randomised trial","volume":"75","author":"Yarnold","year":"2005","journal-title":"Radiother Oncol"},{"key":"R11-20250929","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1470-2045(06)70699-4","article-title":"Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: Long-term results of a randomised trial [published correction appears in Lancet Oncol 2006;7:620]","volume":"7","author":"Owen","year":"2006","journal-title":"Lancet Oncol"},{"key":"R12-20250929","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer:A randomised trial","volume":"9","author":"Bentzen","year":"2008","journal-title":"Lancet Oncol"},{"key":"R13-20250929","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-20250929","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer:10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"R15-20250929","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","article-title":"Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer:A randomised, non-inferiority, open-label, phase 3 trial","volume":"20","author":"Wang","year":"2019","journal-title":"Lancet Oncol"},{"key":"R16-20250929","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death:Meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"key":"R17-20250929","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Danish Breast Cancer Group Radiation Therapy Committee. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase iii trial:The DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol"},{"key":"R18-20250929","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.20.01024","article-title":"Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era:A multicenter, randomized controlled trial from China","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R19-20250929","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-20250929","doi-asserted-by":"crossref","first-page":"920","DOI":"10.5603\/RPOR.a2021.0109","article-title":"Hypofractionated radiotherapy in breast cancer:A 10-year single institution experience","volume":"26","author":"Najas","year":"2021","journal-title":"Rep Pract Oncol Radiother"},{"key":"R21-20250929","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward):5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_282_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:44:07Z","timestamp":1787067847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_282_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_282_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-02-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}